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Combining the scleroderma and Fleischner staging systems in RAILD identifies patients with an IPF-
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encompassed by RAILD measures of disease severity and extent. http://ow.ly/SUcV30mmeYI
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ABSTRACT The aim of this study was to compare radiology-based prediction models in rheumatoid
arthritis-related interstitial lung disease (RAILD) to identify patients with a progressive fibrosis phenotype.
RAILD patients had computed tomography (CT) scans scored visually and using CALIPER and
forced vital capacity (FVC) measurements. Outcomes were evaluated using three techniques, as follows.
1) Scleroderma system evaluating visual interstitial lung disease extent and FVC values; 2) Fleischner
Society idiopathic pulmonary fibrosis (IPF) diagnostic guidelines applied to RAILD; and 3) CALIPER
scores of vessel-related structures (VRS). Outcomes were compared to IPF patients.
On univariable Cox analysis, all three staging systems strongly predicted outcome (scleroderma system
hazard ratio (HR) 3.78, p=9×10−5; Fleischner system HR 1.98, p=2×10−3; and 4.4% VRS threshold HR
3.10, p=4×10−4). When the scleroderma and Fleischner systems were combined, termed the progressive
fibrotic system (C-statistic 0.71), they identified a patient subset (n=36) with a progressive fibrotic
phenotype and similar 4-year survival to IPF. On multivariable analysis, with adjustment for patient age,
sex and smoking status, when analysed alongside the progressive fibrotic system, the VRS threshold of
4.4% independently predicted outcome (model C-statistic 0.77).
The combination of two visual CT-based staging systems identified 23% of an RAILD cohort with an
IPF-like progressive fibrotic phenotype. The addition of a computer-derived VRS threshold further
improved outcome prediction and model fit, beyond that encompassed by RAILD measures of disease
severity and extent.
This article has supplementary material available from erj.ersjournals.com
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Introduction
The development of lung fibrosis in rheumatoid arthritis is recognised in 2–8% of patients [1, 2], but is
associated with a three-fold increased risk of mortality [2]. Given the limited number of patients with
rheumatoid arthritis-related interstitial lung disease (RAILD) undergoing surgical lung biopsies, attention
has focused on evaluating disease patterns on computed tomography (CT) imaging to predict patient
outcomes. Several studies have analysed CT scans in RAILD patients using the idiopathic pulmonary
fibrosis (IPF) CT diagnostic guidelines [3] and demonstrated the poor outcome in RAILD associated with
a usual interstitial pneumonia (UIP) pattern [4–11]. However, despite two studies demonstrating similar
outcomes between RAILD and IPF patients [4, 5], the median survival in RAILD patients with a CT UIP
pattern has varied between 3.2 and 10.2 years [4–6, 8, 10] in different reports.
A potential limitation when extrapolating IPF patterns on CT to RAILD is that the distribution of disease in
RAILD may not be basal-predominant, as honeycomb cysts and reticulation may be concentrated
peripherally in the middle or upper zones of the lungs [12]. Accordingly, an IPF-like definite UIP pattern
with basal predominance on CT may only capture a proportion of RAILD patients with true honeycombing.
Yet, the importance of identifying RAILD patients in whom disease behaviour is relentlessly progressive, or
IPF-like, is increasingly relevant. Mechanistic links between RAILD and IPF are increasingly recognised [13]
and there is emerging preclinical evidence of the potential role in disease modification from antifibrotics in
RAILD [14]. Furthermore, as highlighted in a recent perspective [15], there is growing recognition within
the interstitial lung disease (ILD) community that a predominant focus on IPF may have curtailed the
identification of rapidly progressive fibrotic phenotypes in non-idiopathic conditions.
Therefore, our primary study aim was to identify, on CT imaging in RAILD populations, patients with a
progressive fibrotic phenotype using two staging systems: a system derived in scleroderma evaluating
disease extent [16], and a modification of the Fleischner Society IPF diagnostic guidelines [17]. To avoid
inherent biases associated with the evaluation of patients presenting to a single tertiary centre, we analysed
independent RAILD cohorts presenting to tertiary referral centres in two countries of the United
Kingdom. As a secondary aim, we compared survival in RAILD to survival in patients with IPF, and again
to maintain robustness of our conclusions evaluated an multicentred international IPF population. Our
final aim was to examine whether prognostication using computer analysis of CT imaging in RAILD was
independently predictive of mortality when evaluated against the two RAILD CT staging systems.
Methods
Clinical data
Retrospective analyses of ILD databases identified all new consecutive patients presenting to two teritary
ILD centres, the Royal Brompton Hospital (London, UK) from January 2007 to July 2014, and the
Edinburgh Royal Infirmary (Edinburgh, UK) from January 2005 to December 2015. A diagnosis of
rheumatoid arthritis was made according to the American College of Rheumatology/European League
Against Rheumatism criteria [18] by specialist rheumatologists at both institutions. The presence of a
fibrosing lung disease was initially diagnosed following review by a multidisciplinary team comprising
pulmonologists, radiologists and, when biopsy samples were available, histopathologists. ILD presence was
confirmed during the detailed scoring of the CT scans. Patients were defined as never-smokers following
evaluation of clinical notes if they had a total lifetime tobacco exposure of <100 cigarettes [19].
The RAILD population was compared to 284 IPF patients presenting to the Royal Brompton Hospital
(n=179) and St Antonius Hospital (Utrecht, the Netherlands) (n=105), who were evaluated with
multidisciplinary team diagnosis using consensus guidelines [3]. The Royal Brompton Hospital IPF
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patients comprised consecutive new referrals presenting between July 2011 and December 2014 who had
received a baseline volumetric noncontrast CT scan. The IPF patients presenting to St Antonius Hospital
comprised newly referred patients who had undergone a baseline volumetric noncontrast CT scan between
2004 and 2015.
Approval for this study of clinically indicated CT and pulmonary function data was obtained from the
institutional ethics committees of the Royal Brompton Hospital, St Antonius Hospital and Edinburgh
Royal Infirmary, and informed patient consent was not required.
Visual CT evaluation
CT protocols are described in the online supplementary material. Each CT scan was evaluated
independently by two radiologists (GC and JB) with 3 and 4 years imaging experience, respectively,
blinded to all clinical information. CT patterns quantified on a lobar basis to the nearest 5% included
ground glass opacities, reticular pattern and honeycombing (summed as ILD extent) [20]. Extent of
emphysema and severity of traction bronchiectasis were quantified on a lobar basis, as previously
described [21]. The most disparate 5% of visual scores (equating to two standard deviations) and any
disagreement in presence/absence of honeycombing or emphysema were adjudicated by a third scorer ( JJ)
with 10 years imaging experience, blinded to all clinical information.
In addition, all CT scans were classified into one of five groups using a modification of the Fleischner
Society IPF diagnostic guidelines [17] to allow applicability to a RAILD population (figure 1). The first
modification involved eschewing a mosaic attenuation pattern from the list of inconsistent features
prohibiting a UIP diagnosis. The second modification involved separating disease distribution into that
typical of IPF (peripheral, basal or subpleural predominant) and disease distributions not typical of IPF
(middle or upper zone predominant). The CT scans were classified accordingly into the following five
groups. Group 1: definite UIP pattern in an IPF distribution; group 2: definite UIP pattern not in an IPF
distribution; group 3: probable UIP in an IPF distribution; group 4: probable UIP pattern not in an
IPF distribution; group 5: features inconsistent with UIP (excluding disease distribution and a mosaic
attenuation pattern) (figure 1). The CT scans were scored by a radiologist ( JJ) and a pulmonologist
specialising in ILD (GM). Any discrepancies in scores were compared to a read by a third scorer ( JB), and
a)
d) e)
b) c)
FIGURE 1 Computed tomography (CT) images demonstrating the five groups of the modified Fleischner
staging system. a) In a 55-year-old male ex-smoker, honeycombing is visible in a peripheral, basal subpleural
distribution typical of a classical usual interstitial pneumonia (UIP) pattern on the axial CT image (group 1);
b) a 58-year-old male ex-smoker has honeycomb cysts lying anteriorly above the horizontal fissure on a sagittal
CT image with no basal subpleural honeycomb cysts in the lower lobe periphery (group 2); c) in a 57-year-old
male never-smoker subtle traction bronchiectasis is visible in the peripheral basal subpleural region of the
lower lobes on the axial CT image (group 3); d) a 61-year-old male ex-smoker demonstrates right mid-zone
predominant traction bronchiectasis with sparing of the lung bases (group 4) on a coronal CT image; e) a
70-year-old female ex-smoker has evidence of pulmonary fibrosis in a bronchocentric distribution in the left
lower lobe, with perilobular arcades of consolidation reminiscent of a fibrosing organising pneumonia pattern
in the right lower lobe on the axial CT image; the bronchocentricity to the fibrosis and the organising
pneumonia pattern made the CT inconsistent for a UIP pattern (group 5).
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the majority view taken. In 17 (11%) out of 157 cases where there was disagreement between all three
scorers, adjudication was performed by the original scorers ( JJ and GM).
CALIPER CT evaluation
All CTs were evaluated using CALIPER, as previously described [21]. Patterns scored volumetrically by
CALIPER included ground glass opacities, reticular pattern and honeycombing (summed as ILD extent),
emphysema, normal lung and vessel-related structures (VRS). All parenchymal pattern volumes were
expressed as a percentage of the lung, after correcting for total lung volume calculated by CALIPER.
Pulmonary function tests
Pulmonary function test protocols are described in the online supplementary material. Pulmonary
function tests examined in the current study included forced expiratory volume in 1 s (FEV1), forced vital
capacity (FVC), diffusing capacity of the lung for carbon monoxide (DLCO) and the composite
physiological index.
Statistical analysis
Data are presented as mean±SD, or n (%), where appropriate. Interobserver variation for visual scores was
assessed using the single-determination standard deviation for continuous variables and as the weighted
κ-statistic for ordinal categorical variables. Mean differences between groups were evaluated using a
two-sample t-test for parametric continuous variables, and the Mann–Whitney U-test for medians.
Differences between two categorical variables were evaluated using the Chi-squared test. Statistical
significance was evaluated at a value of p<0.05.
The primary study aim was to identify a progressive fibrotic phenotype in RAILD, and to this end,
univariable Cox proportional hazards analyses were used to evaluate mortality prediction in our RAILD
population using two staging systems previously validated in other diseases. The first system was a
composite staging system developed in scleroderma (scleroderma system) [16], which separates patients
into good- and bad-outcome groups, based on CT ILD extent (bad outcome ⩾20% of total lung volume).
For cases that might be considered indeterminate (15–25% ILD, representing 30% of the current study
population), adjudication was made on the basis of FVC measurements (bad outcome ⩽70% predicted).
The second system was the American Thoracic Society (ATS)/European Respiratory Society (ERS)/
Japanese Respiratory Society ( JRS)/Latin American Thoracic Association (ALAT) consensus diagnosis of a
UIP pattern on CT [3] modified by the Fleischner Society (Fleischner system) [17]. When using the
Fleischner system, patients were categorised into one of five groups, as previously described (figure 1). In
addition, the Fleischner system was analysed as a three-group model by combining both definite and
probable UIP groups (disregarding disease distribution as a discriminator).
As a separate analysis, we evaluated a threshold of pulmonary VRS of 4.4% of the lung, produced by
automated computer-derived CT analytical software (figure 2). The 4.4% threshold, derived by CALIPER,
has been shown to separate good- and bad-outcome IPF groups (VRS threshold).
The three systems (scleroderma, Fleischner and VRS) were evaluated separately in univariable Cox
proportional hazards analysis and together in a multivariable Cox proportional hazards analysis to identify
the contribution of each system to mortality prediction. Multivariable models were adjusted for patient age
(years), male sex, smoking status (never versus ever) and baseline percent-predicted FVC, unless stated.
Model fit was evaluated using Harrell’s C-statistic. Survival estimation was performed via the Kaplan–
Meier method. Assumptions of linearity and proportional hazards were tested by visual inspection of
Martingale residuals and scaled Schoenfeld residuals and were satisfied. Statistical analyses were performed
using SPSS (IBM SPSS Statistics for Macintosh, version 20.0; IBM, Armonk, NY, USA) and R Studio Team
(2015; RStudio: Integrated Development for R, RStudio, Boston, MA, USA).
Results
Baseline data
The final rheumatoid arthritis study population comprised 90 patients presenting to the Royal Brompton
Hospital and 67 patients presenting to Edinburgh Royal Infirmary with a multidisciplinary team diagnosis
of RAILD (online supplementary figure S1). Patients underwent a maximum of 6 years of follow-up, with
one patient censored before the end of the follow-up period. Baseline differences between the populations
at the two institutions are demonstrated in online supplementary table S1, and baseline measures for
the combined population are shown in table 1. Edinburgh Royal Infirmary patients were slightly older
(p=0.03) than Royal Brompton Hospital patients and had less severe/extensive disease as measured using
functional indices (Edinburgh cohort FVC 97.0% versus Brompton cohort FVC 76.0%, p<0.0001) and
https://doi.org/10.1183/13993003.00869-2018 4
INTERSTITIAL LUNG DISEASES | J. JACOB ET AL.
a)
d) e) f)
b) c)
FIGURE 2 Axial computed tomography (CT) image colour maps demonstrating CALIPER-derived
vessel-related structures (VRS; red). VRS represent pulmonary arteries and veins (excluding hilar vessels)
and connected tubular structures, the latter primarily reflecting adjoining regions of fibrosis. a–c) axial
sections in a 71-year-old female 30-pack-year ex-smoker with upper lobe emphysema and fibrosis visible in
the lower lobes (VRS 2.1%); d–f ) axial sections in a 62-year-old female never-smoker with upper
lobe-predominant fibrosis (VRS 7.0%). Nonvascular region captures in the VRS signal are visible in the upper
lobes (d) and adjacent to the right hemidiaphragm (f ).
TABLE 1 Patient age, sex and pulmonary function indices and visually and CALIPER-scored
computed tomography (CT) parameters in patients with rheumatoid arthritis-related interstitial
lung disease (ILD)
Median age years 65
Male/female 71/86
Survival (alive/dead) 103/54
Never-smokers/ever-smokers/current smokers# 45/83/22
Honeycombing presence (yes/no) 59/98
Emphysema presence (yes/no) 107/50
FEV1# % pred 79.5±21.8
FVC# % pred 84.4±24.0
FEV1/FVC# % pred 95.6±13.7
DLCO¶ % pred 47.3±17.7
CPI+ % 42.4±16.6
Visual CT scores %
Total ILD extent 25.1±17.0
Fibrosis extent 21.7±14.2
Ground glass opacity 3.1±6.9
Reticular pattern 18.6±11.3
Honeycombing 3.2±7.5
Total emphysema 7.7±12.1
Traction bronchiectasis severity score (maximum score of 18) 7.7±3.6
CALIPER CT scores %
Total ILD extent 15.6±16.0
Total fibrosis extent 5.6±5.2
Ground glass opacity 10.1±13.5
Reticular pattern 4.7±4.4
Honeycombing 0.9±2.1
Emphysema 2.5±6.8
Normal lung 77.8±17.1
Vessel-related structures 4.0±1.8
Data are presented as numbers of patients or mean±SD, unless otherwise stated. FEV1: forced expiratory
volume in 1 s; FVC: forced vital capacity; DLCO: diffusing capacity of the lung for carbon monoxide; CPI:
composite physiological index. #: n=150; ¶: n=131; +: n=128.
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visual and CALIPER CT scores (Edinburgh cohort visual ILD extent 16.7% versus Brompton cohort visual
ILD extent 31.3%, p<0.0001).
The IPF population comprised 179 patients presenting to the Royal Brompton Hospital and 105 presenting
to St Antonius Hospital. Interobserver variation scores are shown in online supplementary table S2 and
baseline differences between the RAILD and IPF populations are shown in online supplementary table S3.
The combined IPF population was older (median age 69 years versus 65 years in RAILD, p=0.0004) and
more likely to be male (79% versus 45% in RAILD, p<0.0001) than RAILD patients. IPF patients had more
severe/extensive disease as measured using functional indices (FVC 74.2% versus RAILD FVC 84.4%,
p<0.0001) and visual and CALIPER CT scores (IPF visual ILD extent 29.1% versus RAILD visual ILD
extent 25.1%, p=0.01).
Univariable outcome prediction in RAILD
On univariable analysis, visual (fibrosis and honeycombing extents, traction bronchiectasis severity) and
CALIPER (fibrosis and honeycombing extents, VRS) measures of interstitial damage powerfully predicted
outcome. Functional indices were less powerful in predicting outcome at baseline. A positive smoking
history did not predict outcome (table 2).
Outcome prediction using staging systems
When the five-group Fleischner system was examined in RAILD, patients with a definite UIP pattern,
regardless of whether the distribution was IPF-like or not, demonstrated a similar outcome (figure 3a).
Similarly, patients with a probable UIP pattern, regardless of distribution demonstrated similar 3-year and
6-year survival. The weighted κ for the scoring of the five-group Fleischner system was 0.65.
When disease distribution was ignored, and the Fleischner system was recoded into a three-group score
(definite, probable and inconsistent UIP patterns), outcome in patients with a definite UIP pattern was
TABLE 2 Univariable Cox regression analysis demonstrating mortality according to patient age,
sex, visual and CALIPER computed tomography (CT) indices and pulmonary function tests in
patients with rheumatoid arthritis-related interstitial lung disease (ILD)
Patients n Hazard ratio (95% CI) p-value
Age 157 1.03 (1.01–1.06) 0.02
Sex 157 1.79 (1.04–3.06) 0.03
Smoking (never versus ever) 150 1.56 (0.82–2.96) 0.18
Visual score
ILD extent 157 1.03 (1.02–1.04) 1×10−6
Fibrosis extent# 157 1.05 (1.04–1.07) <1×10−6
Ground glass opacity extent 157 0.99 (0.96–1.03) 0.75
Reticular pattern extent 157 1.04 (1.02–1.06) 2×10−6
Honeycombing extent 157 1.06 (1.04–1.09) 1×10−6
Total emphysema extent 157 1.01 (0.99–1.03) 0.28
Traction bronchiectasis severity 157 1.22 (1.13–1.31) <1×10−6
Honeycombing presence 157 2.45 (1.43–4.19) 0.001
CT pattern (5-point scale) 157 0.73 (0.61–0.87) 0.0004
CALIPER score
Total ILD extent 157 1.02 (1.01–1.03) 0.002
Total fibrosis extent# 157 1.12 (1.08–1.17) <1×10−6
Ground glass opacity extent 157 1.01 (1.00–1.03) 0.09
Reticular pattern extent 157 1.12 (1.07–1.18) 3×10−6
Honeycombing extent 157 1.17 (1.08–1.27) 9×10−5
Emphysema extent 157 1.00 (0.96–1.05) 0.96
Normal lung extent 157 0.98 (0.97–0.99) 0.0005
Vessel-related structures 157 1.47 (1.28–1.69) <1×10−6
Lung function indices
FEV1 150 0.99 (0.98–1.00) 0.08
FVC 150 0.98 (0.96–0.99) 0.001
DLCO 131 0.96 (0.94–0.98) 4×10−5
CPI 128 1.05 (1.03–1.07) 1×10−5
ILD extent additionally summed ground glass opacities. FEV1: forced expiratory volume in 1 s; FVC: forced
vital capacity; DLCO: diffusing capacity of the lung for carbon monoxide; CPI: composite physiological index.
#: sum of reticular pattern and honeycombing.
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similar to patients with IPF and worse than patients with a probable UIP pattern (figure 3b). On
univariable Cox regression analysis, the three-group Fleischner system strongly predicted outcome (hazard
ratio (HR) 1.98, 95% CI 1.38–2.85; p=2×10−3; C-statistic 0.67); and the three-point scale is used for
analysis in the remainder of the article. On multivariable analysis, no difference in outcome was identified
between RAILD patients with a definite UIP pattern (regardless of distribution) and IPF patients.
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Group 5
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Good outcome without definite UIP pattern
Bad outcome OR definite UIP pattern
Bad outcome with definite UIP pattern
IPF patients
IPF patients
Bad outcome
Good outcome
IPF patients
VRS >4.4%
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FIGURE 3 a) Kaplan–Meier curves demonstrating mortality for patients with rheumatoid arthritis-related interstitial lung disease (RAILD) subdivided
according to the pattern of fibrosis on computed tomography (CT), based on the Fleischner Society idiopathic pulmonary fibrosis (IPF) diagnostic
guidelines. Group 1 (honeycombing occurring in an IPF-like distribution): 53% 3-year and 6-year survival, n=38; group 2 (honeycombing occurring in
a non IPF-like distribution): 40% 3-year and 35% 6-year survival, n=17; group 3 (fibrosis without honeycombing, occurring in an IPF-like distribution):
75% 3-year and 69% 6-year survival, n=33; group 4 (fibrosis without honeycombing, occurring in a non IPF-like distribution): 85% 3-year and 68%
6-year survival, n=23; group 5 (patients with CT features inconsistent with a universal interstitial pneumonia (UIP) diagnosis; distribution of disease
and mosaic attenuation were not considered to be inconsistent features for the purposes of this RAILD study): 92% 3-year and 75% 6-year survival,
n=46. b) Combined patients from groups 1 and 2 in figure 1a: 48% 3-year and 45% 6-year survival, n=55 and patients in groups 3 and 4 in figure 1a:
76% 3-year and 58% 6-year survival, n=56 while the group of patients with inconsistent CT features in figure 1a remained unchanged. All three
groups were compared to a population of IPF patients: 42% 3-year and 18% 6-year survival, n=284. c) Kaplan–Meier curves demonstrating mortality
for patients with RAILD subdivided according to the scleroderma system into good-outcome and bad-outcome groups, and compared with an IPF
cohort. Patients with >25% interstitial lung disease (ILD) extent on CT were given a score of 1 (bad outcome), while patients with <15% ILD extent on
CT were given a score of 0 (good outcome); patients with 15–25% ILD extent on CT were adjudicated on the basis of forced vital capacity (FVC), with
an FVC >70% predicted accorded a score of 0, and FVC <70% pred was accorded a score of 1. Good-outcome scleroderma system 88% 3-year and
70% 6-year survival, n=88; bad-outcome scleroderma system 50% 3-year and 40% 6-year survival, n=68. IPF patients: 42% 3-year and 18% 6-year
survival, n=284. d) Kaplan–Meier curves demonstrating mortality for patients with RAILD categorised using the scleroderma system and a definite
usual interstitial pneumonia (UIP) pattern on CT (disease distribution and mosaicism were not considered as being inconsistent features of a definite
UIP pattern). Patients with a definite UIP pattern on CT had a score of 1 added to their scleroderma system score. Scleroderma system bad outcome
with a definite UIP pattern: 35% 3-year and 35% 6-year survival, n=36; either scleroderma system bad outcome or definite UIP pattern: 78% 3-year
and 58% 6-year survival, n=50; scleroderma system good outcome without definite UIP: 90% 3-year and 78% 6-year survival, n=70. IPF patients: 42%
3-year and 18% 6-year survival, n=284. e) Kaplan–Meier curves demonstrating mortality for patients with RAILD categorised using a CALIPER
vessel-related structure (VRS) score of 4.4%. VRS score >4.4%: 45% 3-year and 40% 6-year survival, n=51; VRS score <4.4% 82% 3-year and 70%
6-year survival, n=106. IPF patients: 42% 3-year and 18% 6-year survival, n=284.
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On univariable analysis, the scleroderma system strongly predicted outcome (HR 3.78, 95% CI 2.10–6.81,
p=9×10−5; C-statistic 0.69) (figure 3c). When examined in a multivariable model, no difference in
outcome was identified between IPF patients and poor-outcome RAILD patients (categorised using the
scleroderma system). In all multivariable models examining the two staging systems, the results were
maintained when visual or CALIPER ILD extent replaced FVC as a measure of baseline disease severity.
Combining real-world staging systems
In order to identify RAILD patients that demonstrated a progressive fibrotic phenotype, the patients with a
definite UIP pattern on CT (irrespective of disease distribution) in the bad-outcome group of the
scleroderma system were identified and compared to the IPF population (progressive fibrotic system)
(figure 3d; table 3). On univariable Cox mortality analysis, the three-point progressive fibrotic system
strongly predicted outcome (HR 2.46, 95% CI 1.73–3.50; p=1×10−5; C-statistic 0.71). Results were
maintained on multivariable analysis when using FVC, visual or CALIPER ILD extents as measures of
baseline disease severity.
Additional impact of VRS threshold
When the CALIPER VRS threshold of 4.4% was examined, outcome prediction was strong (HR 3.10, 95%
CI 1.81–5.29; p=4×10−4; C-statistic 0.66) (figure 3e). RAILD patients with a VRS ⩾4.4% had a similar
outcome to IPF patients on multivariable analysis, with results maintained when visual or CALIPER ILD
extent replaced FVC as a measure of baseline disease severity.
When evaluated in a multivariable model, adjusted for patient age, male sex and smoking status (never
versus ever), the VRS threshold independently predicted outcome when separately examined with the
scleroderma system (C-statistic 0.78), the Fleischner system (C-statistic 0.75) and the progressive fibrotic
system (C-statistic 0.77) (online supplementary table S4). The results demonstrate the additional
prognostic information provided by quantitative CT measures in fibrosing lung diseases beyond that
captured by visual analysis of CT imaging.
Discussion
Our study has combined two simple staging systems, readily available to clinicians and previously
validated in scleroderma and IPF. On applying these staging systems to RAILD patients, we identified 36
(23%) out of 157 of the RAILD population who demonstrate a progressive fibrotic phenotype, with a
4-year survival that is indistinguishable from patients with IPF. In addition, we have shown the additional
prognostic value of automated CT analysis in patients with RAILD.
The landmark study of KIM et al. [4] was the first direct comparison of outcomes in RAILD with those of
IPF patients. Our findings are in line with that study [4] as a definite UIP pattern, traction bronchiectasis
and honeycombing were all associated with worsened survival and female sex and an increased DLCO were
linked to better outcome. Yet a definite UIP pattern in RAILD was only just significant as an independent
predictor of outcome (p=0.03) in the study by KIM et al. [4], which may relate to the fact that a UIP
TABLE 3 Patient age, sex and forced vital capacity (FVC) and visually and CALIPER-scored computed tomography (CT)
parameters in rheumatoid arthritis-related interstitial lung disease (RAILD) patients designated as having a bad outcome on
the scleroderma staging system and having a definite usual interstitial pneumonia pattern on CT, compared to a population of
idiopathic pulmonary fibrosis (IPF) patients
Progressive fibrosis RAILD cohort IPF cohort Cohort differences p-value
Subjects 36 284
Age years 66 (42–82) 69 (37–92) 0.32#
Male/female 21/15 225/59 0.005¶
Survival (alive/dead) 13/23 95/189 0.75¶
FVC % predicted 66.4±19.3 74.2±19.5+ 0.03
Visual ILD extent 41.3±15.0 29.1±12.1 <0.0001
Visual traction bronchiectasis severity
(maximum score 18)
11.7±2.8 10.2±3.2 0.005
CALIPER ILD extent 23.7±15.0 23.5±16.3 0.94
CALIPER vessel-related structures 5.5±1.5 5.3±1.7 0.41
Data are presented as n, median (range) or mean±SD, unless otherwise stated. Comparisons were made using t-test, unless otherwise stated.
ILD: interstitial lung disease. #: Mann–Whitney U-test; ¶: Chi-squared test; +: n=283 (as one IPF patient did not have baseline FVC).
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pattern in RAILD was evaluated on IPF terms. A basal distribution of disease was a prerequisite for a
definite UIP pattern designation. However, as has been documented previously in RAILD, honeycombing
on CT, indicative of histological UIP, can predominate in the middle and upper lobes in RAILD [12] or
appear bronchocentric [7], causing classification inconsistencies when compared to IPF.
In the current study, when strict IPF diagnostic criteria were used, 38 (24%) out of 157 RAILD patients
had a definite UIP pattern on CT. However, when a broader definition, ignoring disease distribution and
the presence of a mosaic attenuation pattern (which can occur secondary to co-existing small airways
disease in RAILD) was considered, 55 (35%) out of 157 RAILD patients were classified as having a definite
UIP pattern. Patients with either UIP definition (strict or broad) demonstrated similar outcomes which
matched to those of a control IPF population. Importantly, both definitions demonstrated distinct
outcomes when compared to patients classified as probable UIP (using strict and broad definitions)
according to the Fleischner Society IPF diagnostic guidelines [17]. By slightly modifying IPF diagnostic
criteria to better suit patients with RAILD, we have more comprehensively captured patients
demonstrating a bad outcome, and in so doing have confirmed the notion that it is the presence of
honeycombing in RAILD, rather than its location, that best determines patient outcome. The clinical
applicability of the modified Fleischner system is also evident in the acceptable κ between scorers, which
are higher than those documented in the 2011 ATS/ERS/JRS/ALAT diagnostic guidelines [3].
The prognostic strength of the scleroderma staging system in our study reinforces the importance of
disease extent as a predictor of outcome in RAILD, a finding highlighted by SOLOMON et al. [5], where
fibrosis extent was an independent predictor of survival in RAILD. Indeed, once disease extent had been
accounted for, the Fleischner system, though remaining independently predictive of outcome, only added
slightly to the goodness of fit of the model. However, when bad-outcome scleroderma patients with a
definite UIP pattern were subanalysed, they mimicked a progressive fibrotic phenotype, akin to IPF, more
consistently (table 3).
Almost a quarter of our RAILD study population, had extensive and severe (UIP pattern) disease on CT,
which behaved like IPF. As the recognition of similarities in disease mechanisms and phenotypes between
subsets of patients with RAILD and IPF grows [13], RAILD patients demonstrating a progressive fibrotic
phenotype could be considered to be future potential recipients of antifibrotic medication. In the
remainder, monitoring of longitudinal disease behaviour as set out by an ATS/ERS expert group for use in
unclassifiable ILD [22] might best inform identification of a possible progressive fibrotic phenotype.
In addition to the scleroderma staging system and the modification of the Fleischner Society diagnostic
guidelines, we evaluated the utility of automated software on predicting outcome in RAILD. Specifically,
we evaluated the VRS in the lungs (the volume of pulmonary arteries and veins, and surrounding fibrosis,
excluding vessels at the lung hilum), which have been shown to predict outcome in IPF, at a threshold of
4.4% of the lung volume [23]. In patients with a VRS ⩾4.4%, survival at 3 years was almost identical to
IPF patients. As well as independently predicting outcome when analysed alongside the other staging
systems, the VRS threshold improved the fit of both the scleroderma and Fleischner systems, suggesting
that it provides additional information on outcome beyond that encompassed by simple measures of
disease severity and extent. Almost a third of the RAILD population (51 (32%) out of 157 patients) were
above the 4.4% threshold, indicating a degree of sensitivity to the VRS measure, which may have utility in
analyses of large multicentred RAILD populations, as envisioned in a recent RAILD editorial [24], and
where visual scoring of CTs would be impractical.
There were limitations to the current study. While the obvious benefits of automated analysis include its
objectivity and reproducibility, extremely edge-enhancing CT algorithms can result in misclassification of
patterns such as honeycombing. For this reason, in the current study, CTs from three patients with RAILD
CTs reconstructed with a Siemens B60f algorithm were not analysed. To avoid the exclusion of such cases,
the routine acquisition of computer-friendly reconstruction algorithms should be encouraged and will
become increasingly important as quantitative CT analysis becomes more widespread. In addition, the
standardisation of algorithms will improve the likelihood of identifying subtle changes in pattern extents
across serial CT examinations. The RAILD patients in the two study centres had differing disease
severities, with more advanced disease seen in the Royal Brompton Hospital population. However, we
believe that this heterogeneity is a potential strength rather than a major limitation, as it better reflects a
real-world cohort of RAILD patients, rather than a selection of advanced, complex RAILD patients
referred to a single tertiary London centre. It was for this reason that we also chose to compare the RAILD
patients to IPF patients originating from two tertiary centres, instead of a single, homogenous, potentially
biased IPF cohort.
In conclusion, we have demonstrated that by combing two staging systems, we are able to identify RAILD
patients with a CT UIP pattern, demonstrating a progressive fibrotic phenotype. Representing 23% of our
https://doi.org/10.1183/13993003.00869-2018 9
INTERSTITIAL LUNG DISEASES | J. JACOB ET AL.
RAILD population, this cohort had a 4-year survival indistinguishable from patients with IPF. We have
also shown the additional prognostic strength of computer analysis of CT imaging which provides
information on patient outcome in RAILD, beyond that described by visually scored CT pattern extents.
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